- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07649798
Initial Study of a MOTHER-DAUGHTER SIDE-BRANCH ACCESS™ DES System (FIH EFS)
Initial Study of a MOTHER-DAUGHTER SIDE-BRANCH ACCESS™ DES System for Bifurcation Lesions (First-in-Human, Early Feasibility Study)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a prospective, single-arm, single-center initial (EFS) clinical study enrolling subjects with symptomatic ischemic heart disease due to a de novo coronary bifurcation lesion. The objective is to obtain initial insights into the clinical safety of the device-specific aspects of the procedure; whether the device can be successfully delivered and implanted; whether there are any operator technique challenges with device use; human factors; clinical safety of the device and whether the device performs in accordance with its intended purpose.
All enrolled subjects will be treated with the study device during the index procedure and followed after treatment to assess procedural success, clinical safety, and device performance. Follow-up is conducted through 3 years.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Asunción, Paraguay
- Cirugía Cardiovascular, Sanatorio Italiano
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
Be 21 years of age or older. Have symptomatic ischemic heart disease or objective evidence of reduced blood flow to the heart.
Be eligible for PCI, also known as coronary stenting. Have a new coronary artery narrowing involving a branch point that meets the study's angiographic requirements.
Be willing and able to complete study follow-up. Be able to provide written informed consent. If able to become pregnant, have a negative pregnancy test before the procedure and agree not to become pregnant or breastfeed for 1 year.
Exclusion Criteria:
Are currently participating in another investigational drug or device study that could interfere with this study.
Had a coronary intervention within 30 days before the planned study procedure. Need a planned additional coronary procedure soon after the study procedure. Had a prior stent placed close to the target lesion. Have a target lesion that requires certain other treatment devices before stent placement, other than balloon angioplasty or intravascular lithotripsy.
Have a serious medical condition that could limit participation, follow-up, or interpretation of the study results.
Have a life expectancy of less than 3 years. Have a condition requiring chronic immunosuppressive therapy or have a severe autoimmune or immunosuppressive condition.
Have significantly reduced heart pumping function. Had a recent acute heart attack, unless certain laboratory values have returned to acceptable levels.
Had a stroke or transient ischemic attack within the past 6 months. Have certain abnormal blood test results, including low white blood cell count, low neutrophil count, low platelet count, or significantly reduced kidney function.
Have active stomach or intestinal bleeding, active peptic ulcer disease, a bleeding disorder, or cannot receive blood transfusions.
Have a known allergy or contraindication to required medications, contrast dye, or study device materials that cannot be adequately managed.
Are pregnant, breastfeeding, or planning to become pregnant within 1 year after the study procedure.
Have coronary anatomy that is not suitable for the study device, as determined during coronary angiography (This may include blood clot in the target lesion, severe vessel tortuosity, severe calcification, certain lesion locations, or other significant disease in the target vessel).
Are unable or unwilling, in the opinion of the study doctor, to comply with the study requirements.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Fattibilità del dispositivo
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Patients with coronary bifurcation lesions
Patients undergoing PCI to treat a bifurcation lesion
|
The MD-SBA DES System is a single use, minimally invasive combination product that consists of a cobalt chromium metal coronary stent, coated with sirolimus in a PEA/BHT matrix, on a rapid exchange (RX) delivery system.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Procedure Success
Lasso di tempo: Periprocedural
|
To determine whether the device can be successfully delivered and implanted, as measured by attainment of <30% final residual stenosis of the target lesion and no in-hospital major adverse cardiac events (MACE).
|
Periprocedural
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
MACE
Lasso di tempo: 30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
|
Percentage of subjects with major adverse cardiac events, defined as cardiac death, myocardial infarction, emergency coronary artery bypass surgery, or clinically driven target lesion revascularization.
Components of MACE, including cardiac death and myocardial infarction, may also be summarized.
|
30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
|
|
TVF
Lasso di tempo: 30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
|
Percentage of subjects with target vessel failure, defined as cardiac death, target vessel myocardial infarction, or clinically driven target vessel revascularization.
|
30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
|
|
Target Lesion Revascularization of the Side Branch
Lasso di tempo: 30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
|
Percentage of subjects requiring repeat treatment of the side branch by percutaneous or surgical methods.
|
30-days, 6-months, 1-year, 2-years, and 3-years post index procedure
|
|
Stent thrombosis
Lasso di tempo: 6-months, 1-year, 2-years, and 3-years post index procedure
|
Percentage of subjects with late stent thrombosis.
|
6-months, 1-year, 2-years, and 3-years post index procedure
|
|
Acute Success
Lasso di tempo: Index procedure
|
Percentage of subjects with successful device delivery and target lesion treatment, including final residual stenosis <30% and adequate side branch flow.
|
Index procedure
|
|
Side Branch Access
Lasso di tempo: Index procedure
|
Percentage of subjects with TIMI-3 flow in the side branch and/or need to re-cross the side branch after study device use.
|
Index procedure
|
|
Bleeding / Vascular Complications
Lasso di tempo: Hospital discharge
|
Percentage of subjects with bleeding or vascular complications.
|
Hospital discharge
|
|
Procedure Time
Lasso di tempo: Index procedure
|
Duration of the index procedure in minutes
|
Index procedure
|
|
Fluoroscopy Time
Lasso di tempo: Index procedure
|
Total fluoroscopy duration during index procedure in minutes
|
Index procedure
|
|
Contrast Volume
Lasso di tempo: Index procedure
|
Total volume of contrast media used during index procedure in milliliters
|
Index procedure
|
Collaboratori e investigatori
Investigatori
- Direttore dello studio: Randy E David, PhD, Advanced Bifurcation Systems Inc.
- Cattedra di studio: Mehran Khorsandi, MD, Advanced Bifurcation Systems Inc.
- Investigatore principale: Adrian Ebner, MD, Sanatorio Italiano, Asunción, Paraguay
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 082825
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Angioplastica coronarica
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioReclutamentoCoronary Artery DiseaseItalia
-
Tel-Aviv Sourasky Medical CenterCompletatoSoggetti consecutivi che sono idonei per una coronaria | Angioplastica di de Novo Lesion(s) in Native Coronary | Le arterie dovrebbero essere sottoposte a screening per l'idoneità. | Un numero totale di 200 pazienti che soddisfano la selezione | Criteri e disponibilità a firmare il consenso... e altre condizioniIsraele
Prove cliniche su MD-SBA DES System
-
Concept Medical Inc.Attivo, non reclutanteDisfunsione dell'arteria coronaria | Diabete | Sindrome coronarica acutaSvizzera, Australia, Corea, Repubblica di, Francia, Belgio, Olanda, Regno Unito, India, Austria, Bangladesh, Brasile, Cechia, Germania, Irlanda, Italia, Malaysia, Messico, Polonia, Singapore, Svezia, Taiwan